CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Good morning. My name is Maury Raycroft and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome the CEO of CRISPR Therapeutics Sam Kulkarni. Thanks so much for joining us today, Sam. We're going to do fireside chat format. So m ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Samarth Kulkarni Yes, for those who are not familiar with CASGEVY, this is a product where it's an ex vivo cell therapy product. We take patient cells, edit them using CRISPR/Cas9 to produce fetal hemoglobin and the elevated fetal hemoglobin makes up for the deficiency or defectiveness of the adult beta globin. And this was an approach that ...

In keeping with Cathie Wood's style, these picks are riskier than average. Via her ARK Innovation ETF (ARKK 1.25%), portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and temperamental stocks, though investors are lured back time and time again because they offer the possibility of big returns in exchange for significant risks. Does it make sense to invest in these stoc ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this company have returned +3.5%, compared to the Zacks S&P 500 composite's +4.3% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has gained 5%. The key question now is: What could be the stock's future direc ...

There are a handful of different factors that could buoy its stock. As its shareholders already know, CRISPR Therapeutics (CRSP -0.88%) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint blockbuster drugs, and plenty of financial flexibility, there's no shortage of reasons to buy the stock. But even for those who appreciate the company's merits, the picture is likely even sunnier than they realize. Here are three reasons why the sto ...

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer- ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Naimish Patel, M.D., as Chief Medical Officer, effective May 28, 2024. Dr. Patel is an experienced drug developer who has worked across a wide range of d ...

With a gene therapy for two illnesses out the door, and with sales slated to take off over the next few quarters, CRISPR Therapeutics (CRSP -1.28%) is making it a good time to be a shareholder. But could this biotech's halcyon days be so good that a $10,000 investment today could end up being worth millions of dollars? Although such returns may seem wild, history is full of many such wealth-generating events. Let's dive in and explore if investors can bank on CRISPR Therapeutics stock to generate ground- br ...

These biotech stocks have just launched their first products. The stock market is roaring higher, with the Nasdaq and S&P 500 recently extending gains to reach new record highs. But don't worry. It's not too late to get in on this market growth. The indexes confirmed their presence in a bull market earlier this year, but these phases of market optimism tend to last quite some time -- and history shows us they generally go on for much longer than bear markets. In a study spanning 1926 through 2017, the avera ...

In my view, Vertex and CRISPR Therapeutics are well-positioned to grab upwards of 20% of Casgevy's total addressable market. The therapy -- a one-time treatment that should provide patients with a functional cure -- costs $2.2 million per treatment in the U.S., so there is a multibillion-dollar opportunity here. Casgevy: The sky is the limit Developing gene-editing therapies is difficult, but commercializing them is its own challenge. To administer Casgevy, physicians first need to collect the patient's cel ...

CRISPR Therapeutics AG (NASDAQ:CRSP) BofA Securities 2024 Health Care Conference Call May 15, 2024 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Geoffrey Meacham - Bank of America Merrill Lynch Geoffrey Meacham All right. Here we go. Okay. Welcome to the second day of the Bank of America Health Care Conference. So my name is Geoff Meacham, I'm the senior biopharma analyst. We are thrilled today to have CRISPR Therapeutics. And speaking on behalf of ...